Perceived sexual difficulties and associated factors in patients with heart failure
2012 (English)In: American Heart Journal, ISSN 0002-8703, E-ISSN 1097-6744, Vol. 163, no 2, 246-251 p.Article in journal (Refereed) Published
Background Sexual dysfunction is a common problem of increasing incidence in patients with heart failure (HF). However, there is no knowledge on which demographic, clinical, and quality of life (QoL) aspects are related to difficulties in sexual activity nor on the course of sexual difficulties in patients with HF. less thanbrgreater than less thanbrgreater thanMethods Data on sexual difficulties were collected at 1 and 18 months after an HF hospitalization (n = 792, mean age 69 +/- 12 years, 35% female, mean left ventricular ejection fraction 33% +/- 14%) by the question on sexuality of the Minnesota living with HF questionnaire. Demographic and clinical factors were assessed from medical records and QoL by Minnesota living with HF questionnaire, Medical Outcome Study 36-item General Health Survey, and Ladder of Life. less thanbrgreater than less thanbrgreater thanResults In total, 48% (n = 380) of the patients perceive difficulties in sexual activity at 1 month after discharge, and 70% continued to perceive this at 18 months. Furthermore, 27% of the patients without difficulties at 1 month developed them during follow-up. Living with a partner (OR 3.76, 95% CI 2.58-5.48), younger age (OR 0.96, 95% CI 0.94-0.97)), male gender (OR 3.08, 95% CI 2.10-4.43), overall well-being (OR 1.13, 95% CI 1.00-1.27), and physical (OR 1.06, 95% CI 1.06-1.08) and emotional (OR 1.07, 95% CI 1.03-1.10) QoL were independently associated with perceived difficulties in sexual activity. less thanbrgreater than less thanbrgreater thanConclusions Perceived difficulties in sexual activity are common in patients with HF, particularly in younger and male patients and continue over time. Patients who perceive difficulties in sexual activity report a significant lower QoL and overall well-being than those who do not.
Place, publisher, year, edition, pages
Elsevier , 2012. Vol. 163, no 2, 246-251 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-75724DOI: 10.1016/j.ahj.2011.10.011ISI: 000300226600017OAI: oai:DiVA.org:liu-75724DiVA: diva2:508709
Funding Agencies|Netherlands Heart Foundation|2000Z003D97.017|Biosite Europe, France||Roche Diagnostics, The Netherlands||Novartis Pharma BV, The Netherlands||2012-03-092012-03-092012-04-03